Plasma Cholinesterase Activity in Patients During Therapy with Dexamethasone or Prednisone

Bradamante, Vlasta; Kunec-Vajić, E.; Lisić, Miroslav; Dobrić, Ivan; Beus, I

doi:10.1097/00132586-198912000-00008

Cited by 5 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analysts should, however, be aware of in vivo interferences, notably that of toxic inhibition either from the presence of anticholinesterase medications or the presence of OP insecticides. As with all analyses, the possible presence of drug interference should be considered; there is, for example, at least one report of arti¢cially low activity seen in patients on long-term steroid therapy 38 and we have seen interference in the benzoylcholine assay due to antibiotics with a high absorbance in the UV region. Readers are referred to suitable texts such as Young 39 for reviews of drug interferences.…”

Section: Assay Interferencementioning

confidence: 99%

Cholinesterase: phenotyping and genotyping

Goodall

2004

Ann Clin Biochem

View full text Add to dashboard Cite

The plasma enzyme butyrylcholinesterase (BChE) is of clinical interest because of the occurrence of genetic variants with decreased ability to hydrolyse, and therefore inactivate, muscle-relaxant drugs such as suxamethonium. Analysis of BChE involves the determination of both enzyme activity and biochemical phenotypes which are used to determine the risk of so-called 'scoline apnoea'. Problems in analysis arise from both the lack of a universally accepted reference method and the variety of substrates and conditions employed for the determination of activity and phenotypes. Phenotype is determined by the use of speci c enzyme inhibitors that produce phenotype-speci c patterns of 'inhibitor numbers'. DNA analysis is now possible, and true genotypes can be obtained. The nomenclature in use for cholinesterase studies can cause problems in interpretation and reporting as there is poor understanding of the difference between phenotype and genotype, and terms are often, inappropriately, transposed. Techniques for both biochemical and molecular analysis of the enzyme are discussed.

show abstract

Section: Assay Interferencementioning

confidence: 99%

Cholinesterase: phenotyping and genotyping

Goodall

2004

Ann Clin Biochem

View full text Add to dashboard Cite

show abstract

“…In a study on patients with diabetes type I or type II, BuChE activity correlated positively with TG concentration and inversely with insulin sensitivity [14]. 10 Our results show that chronic treatment with GL caused a significant decrease of HDL-cholesterol by 19% and 32% after 6 and 12 weeks of treatments (Table 1).…”

Section: Discussionmentioning

confidence: 56%

“…Therefore, a significant reduction in BuChE activity (e.g., due to liver disease, cancer, uraemia, treatment with glucocorticoids, reversible or irreversible cholinesterase inhibitors, etc.) may increase the intensity and duration of action of succinylcholine and the systemic toxicity of ester-type local anaesthetics [8][9][10]. In contrary, the increase of BuChE activity in anaesthesiology is of minor clinical significance.…”

Section: Introductionmentioning

confidence: 99%

Changes in Butyrylcholinesterase Activity and Serum Lipids after Oxprenolol and Glibenclamide Treatments in Non-diabetic Rats

Bradamante

Krnić

Zrinski

et al. 2011

Arzneimittelforschung

View full text Add to dashboard Cite

SummaryThe effects of chronic treatment with oxprenolol (CAS 6452-72-7) (OXP, 15 mg/ kg/day), or glibenclamide (CAS 10238-21-8) (GL, 2.5 mg/kg/day), or their combination administered for 6 and 12 weeks, on the butyrylcholinesterase (BuChE) activity in plasma and liver and on the plasma levels of triglycerides, total cholesterol and high density lipoprotein (HDL)-cholesterol were studied in normal, non-diabetic female rats. In all treated groups a significant increase of plasma BuChE activity was obtained after 6 weeks of either OXP (46%), or GL (36%) treatment, or of their concurrent application (24%). After 12 weeks of treatment, the increase in enzyme activity was significant only in the OXP group. The BuChE activity in the liver was increased (between 3-25%) in all treated groups except in one during 6 and 12 weeks of treatment. These effects of either OXP or GL, or their combination on BuChE activity in liver suggest their stimulating effects on enzyme synthesis. The changes of total plasma cholesterol in all groups were insignificant. On the other hand, HDLcholesterol was significantly decreased in all treated groups. After 6 weeks of treatment, GL, OXP, or their combination caused a decrease in plasma HDL cholesterol by 19, 50 or 22% respectively, when compared with the control group.After 12 weeks of GL, OXP, or GL+OXP administration, HDL-cholesterol plasma levels in treated groups were 32, 25 and 22% lower than in the control group.Treatment with GL, OXP, or GL+OXP during 6 weeks had no significant effect on triglycerides level. However, after 12 weeks of GL, OXP, or GL+OXP administration, the triglycerides levels were significantly increased (9, 47 and 36%) when compared with the control group. These results have shown, that the increase in BuChE activity might be the first sign of altered triglyceride and lipoprotein metabolism.3

show abstract

“…Decreased serum BChE was observed in patients with chronic inflammation, malnutrition, and malignant disease, serving for instance as a potential biomarker for organ damage and impaired liver function [ 22 ]. Furthermore, an association of decreased BChE levels and advanced tumor stage, cancer cachexia, and poor survival in patients suffering from other gastrointestinal, gynecologic, and urologic malignancies has been described earlier [ 21 , 23 – 25 ]. However, the role of BChE as a prognostic parameter in patients with AEG has not been evaluated so far.…”

Section: Introductionmentioning

confidence: 98%

Preoperative BChE serves as a prognostic marker in patients with resectable AEG after neoadjuvant chemotherapy

Gensthaler

Jomrich

Brugger

et al. 2023

Langenbecks Arch Surg

View full text Add to dashboard Cite

Background Diminished systemic serum butyrylcholinesterase (BChE), a biomarker for chronic inflammation, cachexia, and advanced tumor stage, has shown to play a prognostic role in various malignancies. The aim of this study was to investigate the prognostic value of pretherapeutic BChE levels in patients with resectable adenocarcinoma of the gastroesophageal junction (AEG), treated with or without neoadjuvant therapy. Methods Data of a consecutive series of patients with resectable AEG at the Department for General Surgery, Medical University of Vienna, were analyzed. Preoperative serum BChE levels were correlated to clinic-pathological parameters as well as treatment response. The prognostic impact of serum BChE levels on disease-free (DFS) and overall survival (OS) was evaluated by univariate and multivariate cox regression analysis, and Kaplan–Meier curves used for illustration. Results A total of 319 patients were included in this study, with an overall mean (standard deviation, SD) pretreatment serum BChE level of 6.22 (± 1.91) IU/L. In univariate models, diminished preoperative serum BChE levels were significantly associated with shorter overall (OS, p < 0.003) and disease-free survival (DFS, p < 0.001) in patients who received neoadjuvant treatment and/or primary resection. In multivariated analysis, decreased BChE was significantly associated with shorter DFS (HR: 0.92, 95% CI: 0.84–1.00, p 0.049) and OS (HR: 0.92, 95% CI: 0.85–1.00, p < 0.49) in patients receiving neoadjuvant therapy. Backward regression identified the interaction between preoperative BChE and neoadjuvant chemotherapy as a predictive factor for DFS and OS. Conclusion Diminished serum BChE serves as a strong, independent, and cost-effective prognostic biomarker for worse outcome in patients with resectable AEG who had received neoadjuvant chemotherapy.

show abstract

Plasma Cholinesterase Activity in Patients During Therapy with Dexamethasone or Prednisone

Cited by 5 publications

References 0 publications

Cholinesterase: phenotyping and genotyping

Cholinesterase: phenotyping and genotyping

Changes in Butyrylcholinesterase Activity and Serum Lipids after Oxprenolol and Glibenclamide Treatments in Non-diabetic Rats

Preoperative BChE serves as a prognostic marker in patients with resectable AEG after neoadjuvant chemotherapy

Contact Info

Product

Resources

About